Avalo Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $35 price target.
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics' stock price increased following an upgrade by Oppenheimer from Perform to Outperform, with a new price target set at $35.
April 16, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer upgraded Avalo Therapeutics to Outperform and set a price target of $35, indicating a positive outlook on the stock.
The upgrade by Oppenheimer from Perform to Outperform signifies a strong vote of confidence in Avalo Therapeutics' future performance. The setting of a high price target of $35 further emphasizes the bullish outlook, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100